|
|
Profile
|
Delegates :
Takashi Matsuoka, President |
|
Incorporated :
June 15 , 2005 |
Paid in Capital :
347 Million yen |
Employees :
18 人 |
Address :
2-180 Kamo-cho, Yonago TOTTORI
〒683-0823
|
TEL/FAX :
+81-859-37-3838 / +81-859-37-3833 |
URL：
http://chromocenter.com/ |
Attachment :
|
Mission/Background :
chromocenter Inc. contributes to medical development based on chromosome engineering technology. Using patented artificial chromosome vector, we are currently working on research and development for biopharmaceutical production cells, chromosome therapy and gene therapy.
In addition, we are entrusted with chromosome analysis as “cell evaluation” in the field of chromosome engineering technology.
Our chromosome analysis has been implemented for various medical cells (iPS cells, etc.) and pharmaceutical production cells both from Japan and overseas. In particular, the monoclonality analysis has been introduced by FDA presentation document, by which is used among pharmaceutical companies and contract manufacturing organizations.
With the quote "For many people suffering from illness, we will contribute to the development of healthcare and medical care through cutting-edge chromosome engineering technology." as our corporate philosophy, we contribute to making drug development efficient.
|
|
Technology & Business
|
Technology 1) Artificial Chromosome Vector
Artificial chromosome vector is one of our basic technologies, which consists of many distinguishing features.
A) It is maintained without being inserted into the host chromosome.
B) There is no concern of overexpression or loss of expression because of the adjustable amount of introduction and the long-term stability.
C) There is no restriction on gene length, thus it is possible to introduce gene domains or multiple genes necessary for gene expression and control.
Our company is holding two types of artificial chromosome vectors: human artificial chromosome (HAC) vectors and mouse artificial chromosome (MAC) vectors, which are patented proprietary technologies.
Technology 2) Chromosome analysis technology
We are taking charge of Q-band, G-band, FISH and multi-color FISH analyses. In addition, monoclonality analysis, which is evaluated by FDA, is our original method being consulted by global companies.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Higher-yield production of CHO cell lines
|
Service/Marketing
|
Construction of the cell line that highly expresses a target substance by using an artificial chromosome vector
|
Please contact us for details.
|
Chromosome therapy / gene therapy
|
Discovery
|
Under the joint research with Takeda Pharmaceutical (the use of artificial chromosomes for gene therapy)
|
Please contact us for details.
|
Chromosome analysis
|
Service/Marketing
|
Performing various chromosomal analyses (Q-band, G-band, FISH, multi-color FISH, monoclonality analysis , etc.)
|
Please contact us for details.
|
|
|
|
|
|
|
|
|
|
Highlights
|
Chromosome analyses have been received many requests from global companies.
Especially, the analysis of cell line monoclonality is receiving acclaim.
In addition, regarding the research using artificial chromosome vectors, we are conducting the joint research projects with various companies including Takeda Pharmaceutical Company Limited.
(Recent press releases)
May 2019 : Started the joint research with Takeda Pharmaceutical Company Limited for novel technology development
|
|
Hot news
|
We are looking for the companies and medical professionals, whom would like to conduct the joint research and development of chromosome therapy and gene therapy for rare diseases. Please contact us if you are interested in.
|
|
Alliance strategy
|
As mentioned above, our artificial chromosome vectors enable the large-scale gene transfer which was difficult when applying existing vectors. We are looking forward to alliances with the companies, whom are interested in establishing cell lines with artificial chromosome vector technology and applying them for chromosome therapy and genetic therapy.
|
|
|